Alector lays off 17% of staff after AbbVie-partnered Alzheimer’s asset fails phase 2
Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a string of investigational meds missing the mark in the indication. | Alector’s Abbvie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study,
Alector Plummets After Alzheimer's Drug Trial Fails Primary Endpoint
Shares of Alector tumbled in after-hours trading after the company said its Alzheimer drug candidate, AL002, failed to meet its phase 2 primary endpoint of slowing clinical progression of the disease. The stock was down 33.6% to $2.63 in late trading, well under its 52-week low of $3.49.
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology ...
Stock futures edged lower on Tuesday as sentiment took a hit after President-elect Donald Trump said he would raise tariffs ...
Alector reported a Phase 2 failure for an AbbVie-partnered Alzheimer’s program Monday afternoon and said it will ...
南旧金山 - 专注于神经退行性疾病的生物科技公司Alector, Inc.
Alector ( (ALEC) ) has released its Q3 earnings. Here is a breakdown of the information Alector presented to its investors.Don't Miss our Black ...
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment ...
Investing.com -- Alector Inc.宣布，其用于早期阿尔茨海默症治疗的AL002药物的二期临床试验未能达到减缓疾病进展的主要目标。受此消息影响，该公司股价在盘后交易中暴跌32%。 这家生物制药公司表示，由于试验未能达到主要终点，将终止AL002的长期延伸研究。针对这一发展，Alector还透露计划裁减约17%的员工。
TD Cowen analyst Yaron Werber has maintained their bullish stance on ALEC stock, giving a Buy rating on November 4. Yaron Werber has given his ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback